Document Detail


Experience with liposomal Amphotericin-B in 60 patients undergoing high-dose therapy and bone marrow or peripheral blood stem cell transplantation.
MedLine Citation:
PMID:  8555076     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
60 patients undergoing bone marrow or stem cell transplantation were treated with liposomal Amphotericin-B for documented or suspected mycosis. 34 patients had a prior course of conventional Amphotericin-B with the following adverse effects: increasing creatinine above 1.4 mg/dl (n = 17), increasing creatinine below 1.5 mg/dl (n = 9), no response (n = 6), and clinical side-effects (n = 4). Liposomal Amphotericin-B failed in 6/7 patients with culture-proven mycosis who died from infection with Aspergillus (n = 2) and Candida (n = 4), respectively. One patient with Candida lambica sepsis was cured. No patient with clinically or serologically suspected or diagnosed infection died from mycosis. Liposomal Amphotericin-B was well tolerated in 57 patients, even after side-effects of the conventional formulation. Adverse effects occurred in three cases, requiring the withdrawal of the drug in one patient. Due to toxic side-effects of the high-dose therapy and transplant-related complications, it was difficult to evaluate the influence of liposomal Amphotericin-B on laboratory parameters. Eight patients showed a decrease of creatinine levels, which had increased above normal values under preceding therapy with conventional Amphotericin-B. Liposomal Amphotericin-B is well tolerated in patients undergoing high-dose therapy and bone marrow transplantation. The efficacy of liposomal Amphotericin-B needs to be investigated in randomized studies in comparison with conventional Amphotericin-B.
Authors:
W Krüger; M Stockschläder; B Rüssmann; C Berger; M Hoffknecht; I Sobottka; B Kohlschütter; G Kroschke; N Kröger; M Horstmann
Related Documents :
7204466 - Widespread periarticular new-bone formation in long-term comatose patients.
6144826 - Hyperimmunoglobulinaemia d and periodic fever: a new syndrome.
21541836 - Diagnostic and prognostic value of absence of coronary artery calcification in patients...
15048176 - Bone mineral density and bone scintigraphy in adult saudi female patients with osteomal...
6288936 - Gestational trophoblastic disease. the effect of duration of disease and hcg titer on r...
15699536 - Management of oral anticoagulant in clinical practice: a retrospective study of 187 pat...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  British journal of haematology     Volume:  91     ISSN:  0007-1048     ISO Abbreviation:  Br. J. Haematol.     Publication Date:  1995 Nov 
Date Detail:
Created Date:  1996-02-23     Completed Date:  1996-02-23     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  0372544     Medline TA:  Br J Haematol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  684-90     Citation Subset:  IM    
Affiliation:
Department of Oncology/Haematology, University Hospital Eppendorf, Hamburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Amphotericin B / adverse effects,  therapeutic use*
Antifungal Agents / adverse effects,  therapeutic use*
Aspergillosis / complications,  drug therapy
Bone Marrow Transplantation*
Child
Child, Preschool
Female
Hematopoietic Stem Cell Transplantation*
Humans
Infant
Lung Diseases, Fungal / complications,  drug therapy
Male
Middle Aged
Mycoses / complications,  drug therapy
Neutropenia / complications
Opportunistic Infections / complications
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antifungal Agents; 1397-89-3/Amphotericin B

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Quantitation of human cytomegalovirus DNA in bone marrow transplant recipients.
Next Document:  Autoimmune-prone (NZW x BXSB)F1 (W/BF1) mice escape severe thrombocytopenia after treatment with deo...